ScinoPharm Taiwan is a pharmaceutical company specializing in the development and manufacturing of high-barrier active pharmaceutical ingredients (APIs) and drug products. The company provides integrated CDMO services, covering process development, clinical sample preparation, and commercial-scale production for small molecules and peptides. Its therapeutic focus includes oncology, hematology, central nervous system disorders, cardiovascular diseases, orphan drugs, and metabolic diseases, with active development in GLP-1 related products. ScinoPharm operates FDA- and cGMP-compliant facilities, including a sterile injectable plant, and serves global clients, including top-tier patented and generic pharmaceutical companies. Key subsidiaries include SciAnda (Changshu) Pharmaceutical Ltd., ScinoPharm (Kunshan) Biotech Ltd., and ScinoPharm Biotech Ltd. The company was established in 1997 and has passed multiple FDA inspections with zero deficiencies.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - Specialty & Generic Homepage scinopharm.com
Sector Healthcare IR page scinopharm.com/investor
Tags
active pharmaceutical ingredients, drug products, cdmo services, oncology, hematology, central nervous system, cardiovascular, orphan drugs, metabolic diseases, glp-1, small molecules, peptides, SciAnda (Changshu) Pharmaceutical Ltd., ScinoPharm (Kunshan) Biotech Ltd., ScinoPharm Biotech Ltd.
Press page —

Metrics

Valuation  
Market cap NT$ 14.229B
Market cap (USD) $ 431.887M
P/E 900.00
PEG —
P/BV 1.27
P/S 4.68
P/OCF 18.95
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 1.3%
ROI 1.3%
ROIC 0.96%
Profit margin 4.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -27.1%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -56.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 3.163B 3.406B 3.186B 3.264B 2.762B 3.083B 2.893B 3.524B 3.516B 4.031B 3.955B 4.098B 5.088B 4.573B 3.954B 3.891B
Net profit 136.951M 339.35M 287.056M 353.216M 243.471M 282.067M 216.656M 442.978M 422.367M 658.693M 634.965M 484.143M 1.273B 1.17B 959.355M 1.04B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 16.75 22.05 26.4 25.45 24.65 28.85 — — — — — — — — — —
Price performance 12m -0.24 -0.16 0.04 0.03 -0.15 — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

ScinoPharm Taiwan, Ltd. (ticker 1789.TW), listed in Taiwan.

ETFs Holding ScinoPharm Taiwan, Ltd.

ETF Weight in ETF Shares Market value As of
AVEE 0.01% 26,000 $ 15.501K Nov 16, 2026
DEXC 0.00% 22,000 $ 13.112K Nov 12, 2026
DFEV 0.00% 90,000 $ 53.64K Nov 12, 2026
DFEM 0.00% 301,000 $ 179.398K Nov 12, 2026
DFAX 0.00% 182,000 $ 108.473K Nov 12, 2026
DFAE 0.00% 98,000 $ 58.409K Nov 12, 2026
AVEM 0.00% 2,000 $ 1,192.37 Nov 16, 2026
AVSE 0.00% 1,000 $ 596.19 Nov 16, 2026